SLC52A1, solute carrier family 52 member 1, 55065

N. diseases: 160; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0013595
Disease: Eczema
Eczema
0.070 Biomarker disease BEFREE House dust mite-treated PAR2 over-expressor mouse: A novel model of atopic dermatitis. 31487753 2019
CUI: C0013595
Disease: Eczema
Eczema
0.070 Biomarker disease BEFREE Here, we tested the ability of a cell-penetrating pepducin, PZ-235, to mitigate the potentially deleterious effects of PAR2 in models of atopic dermatitis. 30287285 2019
CUI: C0013595
Disease: Eczema
Eczema
0.070 AlteredExpression disease BEFREE Itch, inflammation, and atopic dermatitis are associated with activation of PAR2. 30471839 2019
CUI: C0013595
Disease: Eczema
Eczema
0.070 Biomarker disease BEFREE In addition, β-carotene significantly suppressed protein expression of TNF-α, IL-1β, and MCP-1 and mRNA expression of TSLP, IL-6, IL-1β, IL-4, IL-5, and Par-2 in AD-like skin tissues. 31292344 2019
CUI: C0013595
Disease: Eczema
Eczema
0.070 Biomarker disease BEFREE These findings may provide clues to understanding the pathological role of DhPKs in skin disorders in which PAR2 is known to be involved, such as atopic dermatitis, Netherton syndrome, and psoriasis. 29458120 2018
CUI: C0013595
Disease: Eczema
Eczema
0.070 AlteredExpression disease BEFREE Persistent kallikrein 5 activation induces atopic dermatitis-like skin architecture independent of PAR2 activity. 28238749 2017
CUI: C0013595
Disease: Eczema
Eczema
0.070 Biomarker disease BEFREE Drugs targeting the nonhistaminergic (PAR2/TRPA1) itch pathway and itch sensitization are promising for treating AD itch. 28614190 2017